RECRUITING Phase 2 ClinicalTrials.gov

Dynamic Changes in Circulating Tumour Cells Protein Expression

Sponsor: Matteo's Friends • ClinicalTrials.gov ID: NCT06314997

Registry updated: 2026-10-13

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating clinician according to standard pathological criteria (standard management). The participants were assigned to trial groups with the use of block randomization stratified according to the enrolling center location metropolitan) and tumor stage (T3 or T4).

Interventions

panitumumab (EGFR inhibitors) (Drug)
Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression

Eligibility criteria

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 2 (scores range from 0 to 5, with higher numbers reflecting greater disability) , * medically able to receive chemotherapy. Exclusion Criteria: * evidence of infective disease before enrollment , * a history of another primary cancer within the previous 3 years, * the presence of synchronous primary colorectal cancer.

Conditions

Objective Responsive Rate (ORR)

Locations

Natalia Malara — Germaneto, Italy, Italy

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment